fda stance on compounded semaglutide Ends GLP-1s: What to Know FDA Warns Against Using Compounded

Many clients notice appetite reduction within the first few weeks

GLP-1 Medications with a simple generic name of "semaglutide", "liraglutide", "tirzepatide", "dulaglutide", "exenatide", "exenatide microspheres", or "insulin degludec/liraglutide" and at least one of: A pharmaceutical class of "ANTI-OBESITY GLUCAGON-LIKE PEPTIDE-1 RECEP AGONIST" or "ANTIHYPERGLYCEMIC - INCRETIN MIMETICS COMBINATION" A pharmaceutical class that contains "GLP-1" A pharmaceutical subclass that contains the text "GLP-1"

This extended half-life is intentionally engineered through structural modifications to the semaglutide molecule, including the addition of a fatty acid side chain that promotes binding to albumin in the blood, thereby prolonging its duration of action

Call 999 if severely unwell with signs of shock or collapse